TISSIUM Raises €60M for Medical Polymer Technology

TISSIUM, a pioneer in programmable biomorphic polymers for tissue repair, has successfully closed a significant financing round totaling €60 million. This capital infusion is earmarked to accelerate the company's commercialization efforts, advance its clinical programs, and further develop its proprietary polymer platform.

The funding comprises a €30 million Series D2 equity financing, which saw robust participation from both new and existing international investors, including prominent US-based funds. This equity component bolsters TISSIUM's financial foundation and shareholder base as it transitions into a commercial-stage medical technology entity.

Complementing the equity raise, TISSIUM has secured a substantial €30 million financing facility from the European Investment Bank (EIB). This debt facility, structured in tranches tied to commercial, clinical, and financing milestones, aligns with the EU's InvestEU initiative, underscoring the strategic importance of innovative healthcare technologies within Europe. The company anticipates drawing the initial €10 million tranche imminently.

This dual-pronged financial strategy provides TISSIUM with considerable operational flexibility. The company is currently focused on the US market launch of its inaugural commercial product, COAPTIUM® CONNECT, which recently received FDA marketing authorization. The funds will also support ongoing clinical trials for applications in nerve repair, hernia repair, and cardiovascular procedures.

The medical device market, particularly in reconstructive surgery and advanced wound care, is experiencing sustained growth driven by an aging population and increasing demand for minimally invasive procedures. TISSIUM's innovative polymer technology addresses critical unmet needs by offering programmable adhesion and sealing capabilities, potentially reducing complications and improving patient outcomes. Comparable deals in the medtech space often see significant investor interest in companies with novel platform technologies addressing large market opportunities.

Christophe Bancel, CEO and co-founder of TISSIUM, highlighted the milestone, stating, "This financing marks an important milestone in TISSIUM’s evolution. Following the FDA marketing authorization of COAPTIUM® CONNECT, we are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform. The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients."

The strategic deployment of this capital is expected to propel TISSIUM through its next phase of growth, solidifying its position in the competitive medical technology sector and expanding the reach of its transformative polymer solutions to a wider patient population.